ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma

ClinicalTrials.gov ID: NCT00193492

Public ClinicalTrials.gov record NCT00193492. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 1, 2026, 1:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Rituximab +/- Bevacizumab in the Treatment of Patients With Follicular Non-Hodgkin's Lymphoma: A Randomized, Phase II Trial

Study identification

NCT ID
NCT00193492
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
SCRI Development Innovations, LLC
Other
Enrollment
60 participants

Conditions and interventions

Interventions

  • Bevacizumab Drug
  • Rituximab Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 31, 2005
Primary completion
Feb 28, 2013
Completion
Feb 28, 2013
Last update posted
Jan 4, 2015

2005 – 2013

United States locations

U.S. sites
22
U.S. states
13
U.S. cities
20
Facility City State ZIP Site status
Northeast Arkansas Clinic Jonesboro Arkansas 72401
Florida Cancer Specialists Fort Myers Florida 33901
Integrated Community Oncology Network Jacksonville Florida 32256
Watson Clinic for Cancer Research Lakeland Florida 33805
Florida Hospital Cancer Institute Orlando Florida 32804
Medical Oncology Associates of Augusta Augusta Georgia 30901
Northeast Georgia Medical Center Gainesville Georgia 30501
Wellstar Cancer Research Marietta Georgia 30060
Providence Medical Group Terre Haute Indiana 47802
Graves-Gilbert Clinic Bowling Green Kentucky 42101
Baptist Hospital East Louisville Kentucky 40207
Norton Cancer Institute Louisville Kentucky 40207
Hematology Oncology Clinic, LLP Baton Rouge Louisiana 70809
Center for Cancer and Blood Disorders Bethesda Maryland 20817
National Capital Clinical Research Consortium Bethesda Maryland 20817
Methodist Cancer Center Omaha Nebraska 68114
Hematology Oncology Associates of Northern NJ Morristown New Jersey 07960
Oncology Hematology Care Cincinnati Ohio 45242
Berks Hematology Oncology Associates West Reading Pennsylvania 19611
Spartanburg Regional Medical Center Spartanburg South Carolina 29303
Chattanooga Oncology Hematology Associates Chattanooga Tennessee 37404
Tennessee Oncology, PLLC Nashville Tennessee 37023

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00193492, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 4, 2015 · Synced May 1, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00193492 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →